Acknowledgements
Diamond Partner
Bayer
Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. In just over a decade, the advancing oncology portfolio at Bayer has expanded significantly and includes four marketed products, as well as several investigational compounds in clinical development. We are driven every day by what matters most to the cancer community and work hard to transform the lives of people impacted by cancer, fueled by science and innovation.
Platinum Partner
Eisai
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to help address unmet medical needs.
In March 2018, Eisai and Merck, known as MSD outside the U.S. and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA® (lenvatinib). Under the agreement, the companies will jointly develop and commercialize LENVIMA®, both as monotherapy and in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab).
To learn more, visit www.eisai.com/US.
Gold Partners
Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing and delivering innovative medicines for patients with serious diseases. We are focused on helping patients in disease areas including oncology, cardiovascular, immunoscience and fibrosis. Each day, our employees work together for patients – it drives everything we do.
BTG Interventional Oncology
BTG Interventional Oncology is transforming the cancer care with smarter solutions. Our treatments include elegant and innovative new medicines, improved device technology and ground-breaking delivery techniques. Healthcare is evolving and we believe intelligent science is the way forward.
To learn more about BTG Interventional Oncology, please visit: btg-io.com.
Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. For more information about Exelixis, please visit www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis, Inc. on Facebook.
Lilly
For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.
Exhibitors
Genentech
For more than 40 years, we’ve been following the science, seeking solutions to unmet medical needs. As a proud member of the Roche Group, we make medicines to treat patients with serious medical conditions. We are headquartered in South San Francisco, CA, USA.
Argon Medical Devices
At Argon Medical, we take pride in our mission to improve the lives of patients and caregivers through the innovation, manufacturing and delivery of best-in-class medical devices and superior service. This commitment inspires each and every employee to take ownership of their role and demonstrates how we, as a company, take pride in the work we do.
Media Partners
